Traders Union
All News
Innovative treatments and biotech updates from Viridian Therapeutics

Advertiser Disclosure

Innovative treatments and biotech updates from Viridian Therapeutics

Viridian Therapeutics will host webcast to present VRDN-008 data: Can VRDN break above $29.58?

Ivan Andriyenko
21 hours ago

Viridian Therapeutics will host webcast to present VRDN-008 data: Can VRDN break above $29.58?

Viridian Therapeutics will host a webcast to present data from its VRDN-008 phase 1 clinical trial and outline development plans for its FcRn portfolio. Shares are little changed on the day, ...

Viridian Therapeutics reported Q3 2026 results and business updates after muted trading session

Mykhailo Ihnatenko
04.11.2026

Viridian Therapeutics reported Q3 2026 results and business updates after muted trading session

Viridian Therapeutics reported its third quarter results and outlined progress in its pipeline. The stock edges lower on the day, trading at $25.15.Viridian Therapeutics reported its financial ...

Viridian Therapeutics will report Q3 2026 results and provide a business update after stock ends session up 8%

Andrey Mastykin
21.10.2026

Viridian Therapeutics will report Q3 2026 results and provide a business update after stock ends session up 8%

Viridian Therapeutics will report its third quarter 2026 financial results and provide a business update on November 4. The stock is up 8% on the day at $22.43.Viridian Therapeutics will report ...

Viridian Therapeutics stock edges higher to $21.07 as bullish trend nears overbought zone

Hanna Syniavska
06.08.2026

Viridian Therapeutics stock edges higher to $21.07 as bullish trend nears overbought zone

Viridian Therapeutics reported its second quarter 2026 earnings and recent progress updates. At the same time, Viridian Therapeutics stock is up 1.1% on the day at $21.07.The post, published by ...

Viridian Therapeutics stock jumps 2.93% as FDA clears new thyroid eye disease medicine, Viridian Therapeutics says

Parshwa Turakhiya
27.06.2026

Viridian Therapeutics stock jumps 2.93% as FDA clears new thyroid eye disease medicine, Viridian Therapeutics says

Viridian Therapeutics received FDA approval for its new medicine for Thyroid Eye Disease. The company announced the milestone on social media.Viridian Therapeutics stated that this approval ...

Viridian Therapeutics stock consolidates below key resistance with weak momentum signals

Oleg Tkachenko
09.06.2026

Viridian Therapeutics stock consolidates below key resistance with weak momentum signals

Viridian Therapeutics says it is driven by a belief that people living with autoimmune and rare diseases deserve better medicines.The company is seeking new employees who are impact-driven, ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.